Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors

Next Previous
Trial Profile

A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Flucytosine (Primary) ; TG 6002 (Primary)
  • Indications Carcinoma; Colorectal cancer; Gastrointestinal cancer; Liver metastases
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms TG6002.02
  • Sponsors Transgene

    • Most Recent Events

    • 08 Mar 2024 This trial has been discontinued in Belgium, According to European Clinical Trials Database record.
    • 21 Jun 2023 Status changed from recruiting to discontinued. Study has been terminated after Phase I part on 23 February 2023.
    • 28 Apr 2023 This trial has been discontinued in Spain (Date of the global end of the trial: 23-Feb-2023), according to the European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top